Biocompatibility evaluation of various blood purification therapies
Not Applicable
- Conditions
- Patients with end-stage renal failure undergoing hemodialysis
- Registration Number
- JPRN-UMIN000040267
- Lead Sponsor
- Kawashima hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 16
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with C-reactive protein (CRP); 0.3 mg / dL or more by prior blood test
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method White blood cell count, platelet count, high-sensitivity CRP, plateletderived micro particles change rate and PTX3, IL-6 production rate before and after treatment
- Secondary Outcome Measures
Name Time Method Albumin leakage, transmembrane pressure difference